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Abstract
Synthetic biology is an emerging and promising interdisciplinary 
field of research. Synthetic biology deals with the design of new 
biological units, devices to build artificial life, or the redesign of 
existing natural biological systems with possible applications with-
in many diverse areas such as energy, environment, food, and med-
icine. In this way, synthetic biology may help solve some of the 
challenges the world is facing in the 21st century. However, it is of 
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the utmost importance to consider, at an early stage, the ethics of 
new emerging technologies such as synthetic biology and nanosci-
ence. In this article, we argue that analogues can be drawn between 
nanoscience and synthetic biology. Firstly, we show that the ethical 
principles of beneficence, nonmaleficence, respect for autonomy, 
and justice are important for nanoscience, and we reveal that these 
principles are part of the bioethical theory of the American ethicists, 
Tom L. Beauchamp and James F. Childress. Secondly, we argue that 
analogues can be drawn between the ethical problems of nanosci-
ence and those of synthetic biology, and thirdly, we conclude that 
the theory of Beauchamp and Childress can also be used to analyze 
ethical issues of synthetic biology. In this article we use an oncolytic 
poxvirus for delivery and expression of transgenes in tumors as an 
example to illustrate how to use Beauchamp and Childress’ theory 
to analyse ethical problems of synthetic biology.
Keywords # 1 Synthetic biology, # 2 Ethical assessment,  # 3 Ethi-
cal framework, # 4 the four principles of biomedical ethics.
Introduction
With its visions of designing and constructing new biological parts, 
devices and systems, as well as re-designing existing, natural bio-
logical systems for useful purposes such as pharmaceuticals and en-
ergy, synthetic biology has been declared one of tomorrow’s emerg-
ing fields (www.syntheticbiology.org). Researchers within the 
disciplines of physics, chemistry, molecular biology, biology, biolog-
ical modeling, engineering, and information technology interact in a 
truly interdisciplinary setting across traditional disciplinary bound-
aries to develop the fundamental concepts of synthetic biology. Sci-
entists conduct basic research such as the synthesis of DNA sequenc-
es as bricks (so-called Biobricks) designed to fit into cells, they 
explore the possibility of combining DNA sequences, genes, cells, 
and cell parts with electrodes, metal surfaces, and nanofibers. The 
area of synthetic biology has many potential applications with soci-
etal impact, at present the applied activities within synthetic biology 
are mainly focused on energy, cleaning of chemical pollution, and 
the development of new pharmaceuticals with fewer side effects.
Synthetic biology focuses on the design and construction of new 
biological systems which cannot be found in nature. It is a field of 
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science and engineering that currently includes a number of sub-
fields such as for example:
• “Engineering DNA-based biological circuits, including but not 
limited to standardized biological parts;
• Defining a minimal genome/minimal life (top-down approach);
• Constructing so-called protocells, i.e. living cells, from scratch 
(bottom-up approach);
• Creating orthogonal biological systems based on a biochemistry 
not found in nature; and
• Gene and genome analysis” (Schmidt, 2009).
A concrete example of research into synthetic biology is the idea to 
use a bottom-up approach to design a protocell called ‘The Los Ala-
mos Bug’ from non-living organic and inorganic materials by Ras-
mussen et al. (2003, 2004). The vision is to build a protocell consist-
ing of three entities: Genetic material, a metabolic system, and a 
nano-container. The metabolic system envisioned to be implement-
ed is supposed to form the components of the container which self-
assemble into an aggregate in water, and this aggregate contains the 
metabolism and the genes. Furthermore, it catalyzes gene self-rep-
lication and metabolic processes. The design of this protocell is 
much simpler than biological cells and it allows the design of con-
tainers of few nanometers in diameter (much smaller than existing 
cells) (http://www.istpace.org/Web_Final_Report/WP_1_artifi-
cial_cells_conception/the_los_alamos_bug/index.html). To illus-
trate that the design of the protocell is simpler than biological cells, 
it can be mentioned that instead of RNA, Rasmussen et al. (2003, 
2004) seek to use non-biological molecules such as peptide nucleic 
acids (PNAs), since these are simpler to couple with the lipid layer 
and easier to synthesize than RNA. Also, instead of biological ri-
bozymes, they plan to use simple short oligomers which can self-
replicate without enzymes by a ligation mechanism. Rasmussen et 
al. (2004) originally used computer simulations to predict the life 
cycle of the protocell. By now experiments in the laboratory have 
demonstrated the light-driven metabolism to synthesize lipids. 
However, the other parts of the life cycle have not yet been demon-
strated in the laboratory (Rasmussen et al., 2004).   
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Whereas synthetic biology in general offers many visions, it also 
offers perils such as the accidental release of redesigned organisms 
or the re-engineering of microorganisms or living systems with the 
purpose to harm by terrorist organizations (Serrano, 2007). Ac-
cording to the Austrian biosafety scientist Markus Schmidt, “Syn-
thetic biology is developing rapidly as a new branch of biotechnol-
ogy, with many anticipated benefits and a high impact on society. 
As a result, the societal aspects of this discipline, as well as its pos-
sible risks, are becoming increasingly prominent. It is therefore 
crucial that the societal dimensions develop side by side with the 
field” (Schmidt et al., 2009). Helge Torgersen has studied the soci-
etal dimensions of synthetic biology and suggests comparing the 
introduction of synthetic biology with the introduction of nano-
technology in the early 1990s. Both disciplines “belong to the set of 
converging technologies … as they are novel, assumed to become 
key enabling technologies and to provoke concerns regarding pub-
lic acceptance” (Torgersen, 2009).
Along the same lines, we argue in this article that analogues can 
be drawn between ethical issues of synthetic biology and ethical 
issues of nanoscience, biotechnology, biology, and healthcare, which 
have been analyzed for years in several ethical studies. From these 
reflections a knowledge base has been developed which can serve 
as the foundation for ethical analyses of synthetic biology. We argue 
that basic ethical principles as presented in the bioethical theory of 
principles of the American ethicists, Tom L. Beauchamp and James 
F. Childress, constitute a promising framework for ethical reflec-
tions on synthetic biology (Ebbesen et al., 2006; Beauchamp & Chil-
dress, 2013). However, it is still being debated what approach to use 
in the analysis of ethical issues of synthetic biology. The British pro-
fessor of the sociology of scientific knowledge Steven Yearly (2009) 
doubts that Beauchamp and Childress’ approach is a profound way 
to analyze the ethics of synthetic biology. However, as we will see 
later in this article, we find that he declines the use of Beauchamp 
and Childress’ approach by citing an article that misinterprets their 
theory significantly in philosophical terms.
Several researchers agree that the ethics of synthetic biology 
does not need a quite new ethical methodology. Rather, as we shall 
argue below, existing ethical methodologies need to be used in 
new technological contexts (Parens et al., 2008; Schmidt et al., 
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2008). Furthermore, Ainsley Newson, a senior lecturer in biomedi-
cal ethics at the University of Bristol, points out that founding the 
discipline of ethical analysis of synthetic biology offers the oppor-
tunity of shaping this discipline as an interdisciplinary field, where 
ethicists learn from law and social science and vice versa. Accord-
ing to Newson, this would provide a rich reflection on synthetic 
biology (Newson, 2011). We find this an interesting perception, 
and suggest that this interdisciplinary approach should be even 
broader, including researchers from science and health science as 
well, since synthetic biology includes these fields. This would pro-
vide ethicists the opportunity to be updated with news about sci-
ence in the field and it would provide scientists the opportunity to 
gain insight into ethical reflections.  
We begin with a discussion of the ethics of nanoscience and sub-
sequently draw analogues to that of synthetic biology. First, we pre-
sent some ethical aspects of nanoscience, and by showing that these 
ethical issues resemble ethical issues of biotechnology, biology, and 
healthcare, we argue that ethical issues of nanoscience are not new 
and unique. Next, we examine which basic ethical principles are at 
stake in nanoscience and demonstrate that these principles are part 
of the bioethical theory of Beauchamp and Childress (Ebbesen et al., 
2006). Then, we present some predicted ethical issues of synthetic 
biology and illustrate that these are similar to ethical issues of bio-
technology, biology, and healthcare. As with nanoscience, we exam-
ine which basic ethical principles play a role within synthetic biol-
ogy and show that these are included in Beauchamp and Childress’ 
theory, which therefore can be used to analyze ethical issues of syn-
thetic biology. Lastly, we present the bioethical theory of Beau-
champ and Childress and show how it can deal with the ethical 
problems of synthetic biology by using an oncolytic poxvirus for 
delivery and expression of transgenes in cancer cells as a model 
system. The focus of this article is the practical ethical issues of na-
noscience and synthetic biology, rather than the, admittedly, impor-
tant foundational ethical issues of these fields, such as the relation 
between human and nature, the relationship between human and 
artificial life, and the moral status of designed artificial organisms. 
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Ethics of nanoscience
Fifteen years ago, the nanoscience era started, research into nano-
science advanced rapidly, and the field attracted much visibility 
and funding (http://www.nano.gov/about-nni/what). Research-
ers within physics, chemistry, biology, molecular biology, and med-
icine took a more interdisciplinary approach and focused their 
work on research fields which required input from more than one 
discipline, for instance, biocompatible materials such as implants, 
chemical synthesis, and gene delivery by nanoparticles to cells. 
In 2003, however, researchers from the University of Toronto 
Joint Centre for Bioethics in Canada cautioned that there was a scar-
city in ethical reflections on nanoscience (Mnyusiwalla et al., 2003). 
These authors conducted a survey of databases and found a short-
age of publications on the ethical and social implications of nanosci-
ence. From this they concluded that reflections on ethical issues of 
nanoscience lagged behind research into nanoscience itself, which 
was developing fast. However, in Ebbesen et al. (2006), we disputed 
this conclusion. We questioned whether the fact that there was a 
shortage of published articles on the ethical dimensions of nanosci-
ence implied that the ethical issues of nanoscience had not yet been 
analyzed. We proposed that the ethical aspects of nanoscience are 
analogue the ethical issues of biotechnology, biology, and health-
care, which have been reflected upon by ethicists at least since the 
1970s. From these reflections a knowledge base has been developed 
which functions as a foundation for ethical analyses of nanoscience. 
Furthermore, we argued that basic ethical principles, such as the 
bioethical theory of principles of Beauchamp and Childress, are a 
promising approach for ethical reflections on nanoscience (Ebbesen 
et al., 2006; Beauchamp & Childress, 2013).
Below in figure 1 we have listed some examples of ethical issues 
of nanoscience which are pointed out in the general literature 
(Ebbesen et al., 2006). Furthermore, we have drawn analogies to 
known ethical issues of biotechnology, biology, and healthcare to 
argue that these ethical issues of nanoscience cannot be considered 
new and unique (Ebbesen et al., 2006).
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Ethical issues of nanoscience Ethical considerations Basic ethical principles
Uncontrolled proliferation of self-replicating 
nanosystems
Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence (not harming)
Toxicity of nanoparticles Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence
Ethical issues of nanoscience Analogues to known ethical issues of 
biotechnology, biology, and healthcare 
Uncontrolled proliferation of self-replicating 
nanosystems
Dispersal of gene-modified organisms (GMOs)
Toxicity of nanoparticles Dispersal of GMOs
Toxicity of asbestos
Biological warfare and terrorism September 11th (anthrax powder)
Invasion of privacy as a result of the creation of 
genetic databanks
Biobanks in healthcare in general (for instance the storage of 
blood samples)
Enhancement of human capabilities Enhancement of human capabilities by gene ‘therapy’
Costs and research priorities with regard to 
nanoscience
Costs and research priorities with regard to biotechnology
Access to nanoscience and nanotechnology Access to biotechnology and healthcare in general
Patents, ownership, commerce of nanoscience Patents, ownership, commerce of biotechnology
Figure 1. Ethical issues of nanoscience and analogues drawn to known ethical issues of biotechnology, 
biology, and healthcare (Ebbesen et al., 2006).
In figure 2 we have examined which ethical considerations and ba-
sic ethical principles are at stake within nanoscience (however, we 
do not claim that the list is complete). As demonstrated by red 
marking in figure 2, the ethical issues of nanoscience fall into three 
categories: 1) Risk-benefit analysis, 2) Informed consent, and 3) 
Fairness. In the following, we will show how the four basic ethical 
principles of nonmaleficence, beneficence, respect for autonomy, 
and justice are at stake in these three groups of ethical issues. 
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1) Risk-benefit analysis
According to Beauchamp and Childress, a risk-benefit analysis is an 
evaluation of possible risks in relation to possible benefits, hence a 
ratio between the probability and magnitude of an anticipated 
benefit and the probability and magnitude of an anticipated harm 
(Beauchamp & Childress, 2013, p. 232). This often leads to a judg-
ment about the tolerability of the risks under assessment. Within 
ethics, a risk-benefit analysis is essentially a balancing of the princi-
ples of nonmaleficence and beneficence. The concept of nonmalefi-
cence has been explained by the concept of harm, and according to 
Beauchamp and Childress, “significant bodily harms and other set-
backs to significant interests are paradigm instances of harm” (Beau-
champ & Childress, 2013, p. 152). They focus on “physical harms, 
especially pain, disability, suffering, and death, while still affirming 
the importance of mental harms and other setbacks to one’s inter-
ests” (Beauchamp & Childress, 2013, pp. 152-153). In biomedicine 
and healthcare the concept of benefit often means something posi-
tive such as health or quality of life. 
Ethical issues of nanoscience Ethical considerations Basic ethical principles
Biological warfare and terrorism Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence
Invasion of privacy as a result of the creation 
of genetic databanks
Informed consent Respect for autonomy
Enhancement of human capabilities Who should be offered access to 
enhancement?
Fairness
Justice
Costs and research priorities with regard to 
nanoscience
Fairness Justice
Access to nanoscience and nanotechnology Who should be offered access to 
nanoscience and 
nanotechnology?
Fairness
Justice
Patents, ownership, commerce of 
nanoscience
Fairness Justice
Figure 2. Ethical issues, ethical considerations, and basic ethical principles of nanoscience. However, 
we do not claim that this list is complete and covers all ethical concerns and ethical principles of 
nanoscience (Ebbesen et al., 2006).
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2) Informed consent
Informed consent is based on the assumption that the person in 
question has the capacity to act intentionally, with understanding, 
and without controlling influences determining the action. Gener-
ally, the justification of informed consent is to protect autonomous 
choice and hence the principle of respect for autonomy is the ba-
sis for the practice of informed consent (Beauchamp and Childress, 
2013, pp. 102, 114-15). 
3) Fairness
The term fairness is usually closely connected to the concept of 
justice. This includes the fair distribution of goods in society which 
is particularly important if goods and services are in short supply. 
Here, valid principles of justice can be used to determine how 
social burdens and benefits ought to be allocated (Beauchamp & 
Childress, 2013, p. 249). Hence, there are good reasons to claim that 
the basic ethical principles at stake within nanoscience are nonma-
leficence, beneficence, respect for autonomy, and justice. These 
principles are part of the bioethical theory developed by Beau-
champ and Childress (2015), which we have argued constitutes a 
profound approach for the analysis of ethical issues of nanoscience 
(Ebbesen et al., 2006).
In the next section, we will draw analogues to the ethics of syn-
thetic biology and subsequently return to the use of the bioethical 
theory of Beauchamp and Childress to analyze ethical issues of 
synthetic biology. 
Ethics of synthetic biology
During the last years, the ethical dimensions of synthetic biology 
have got some visibility. For instance, the funding agencies try to 
integrate ethical considerations of synthetic biology as part of scien-
tific research by requiring ethical analysis as part of applications for 
funding. This has been done in the UK where four research councils 
have funded seven scientific networks incorporating ethical reflec-
tions. Also, the European Commission’s Seventh Framework Pro-
gram funds a project called SYNBIOSAFE having an ethical compo-
nent. And lastly, the National Science Foundation in the US finances 
projects incorporating ethical reflections from the beginning (Cal-
vert & Martin, 2009). Furthermore, the American Presidential Com-
kvarter
a ademisk
academic quarter
Volume
12 212
A conceptual framework for the ethics of synthetic biology
Mette Ebbesen, Svend Andersen, Finn Skou Pedersen
mission for the Study of Bioethical Issues has analysed the ethics of 
synthetic biology and formulated certain directions and principles 
to ensure that synthetic biology can be developed in an ethically re-
sponsible manner (Presidential Commission for the Study of Bioeth-
ical Issues, Dec. 2010). Unfortunately, according to  a scorecard, only 
seven of the eighteen recommendations of the presidential advisory 
panel have actually been implemented (Pittman, 2012).
In figure 3, we have listed some predicted ethical issues of syn-
thetic biology, which appear in the general literature (Schmidt et 
al., 2009; Schmidt, 2009; Serrano, 2007; Caplan, 2009; Presidential 
Commission for the Study of Bioethical Issues, Dec. 2010; Synthet-
ic Biology. Introduction to a Debate). Furthermore, we have drawn 
analogies between the predicted ethical issues of synthetic biology 
known ethical issues of biotechnology, biology, and healthcare, in 
the figure. 
Ethical issues of synthetic biology Analogues to known ethical issues of 
biotechnology, biology, and healthcare
Protection of employees working with biotechnological 
processes (design of DNA, artificial cells etc.)
Protection of employees working with 
biotechnological processes
Runaway proliferation of self-replicating artificial (non-
natural) systems
Dispersal of GMOs
Possible toxic nature of designed artificial systems 
dispersed in the environment
Dispersal of GMOs
Toxicity of asbestos
Misuse for weapons or terrorism September 11th (anthrax powder)
Costs and research priorities of synthetic biology Costs and research priorities with regard to 
biotechnology
Access to synthetic biology Access to biotechnology and healthcare in general
Priorities with regard to healthcare
Risks associated with test of new treatments (for 
instance based on self-replicating systems)
Dispersal of viruses used in gene therapy 
Patents, ownership, commerce of synthetic biology Patents, ownership, commerce of biotechnology 
Figure 3. Predicted ethical issues of synthetic biology and analogues drawn to known ethical issues of 
biotechnology, biology, and healthcare (Schmidt et al., 2009; Schmidt, 2009; Serrano, 2007; Caplan, 2009; Presiden-
tial Commission for the Study of Bioethical Issues, Dec. 2010; Synthetic Biology. Introduction to a Debate).
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In figure 4, we have examined the ethical considerations and ba-
sic ethical principles at stake within the ethical issues of synthetic 
biology.
As in nanoscience, the ethical considerations of synthetic biology 
fall into three groups: 1) Risk-benefit analysis, 2) Informed consent, 
and 3) Fairness (figure 4). And as explained above, the following 
Ethical issues of synthetic biology Ethical considerations Basic ethical principles
Protection of employees Health impact
Private sphere / informed consent
Beneficence
Nonmaleficence
Respect for autonomy
Self-replicating artificial (non-natural) 
systems
Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence
Toxic nature of artificial systems Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence
Misuse for weapons/ terrorism Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence
Costs and research priorities with regard 
to synthetic biology
Fairness Justice
Access to synthetic biology Who should be offered access to 
synthetic biology?
Priorities with regard to healthcare
Fairness
Justice
Risks associated with test of new 
treatments (for instance based on self-
replicating systems) 
Environmental impact
Health impact
Risk-benefit analysis
Informed consent
Beneficence
Nonmaleficence
Respect for autonomy
Patents, ownership, commerce of 
synthetic biology
Fairness Justice
Figure 4. Ethical issues, ethical concerns, and basic ethical principles of synthetic biology.
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basic ethical principles can be found from these three ethical con-
siderations: Nonmaleficence, beneficence, respect for autonomy, 
and justice. These ethical principles are part of several ethical theo-
ries. Here, we follow Beauchamp and Childress’ theory because 
this theory contains all the relevant principles and has been criti-
cally developed by the authors through the last thirty years.
The principles of biomedical ethics 
of Beauchamp and Childress
The nature of morality 
Beauchamp and Childress argue that the four basic principles of 
respect for autonomy, beneficence, nonmaleficence, and justice 
form the foundation of a common morality across cultures. Ac-
cording to their theory, everybody committed to morality knows 
the general norms of not to steal, to tell the truth, not to kill, and to 
rescue persons in danger. These are examples of norms found in 
the common morality. Since the norms or rules are cross-cultural, 
we can judge cultures by use or according to these rules.  So, the 
common morality has a normative force and all human conduct 
can rightly be judged by its criteria. This means that if persons do 
not live up to the demands of the common morality they are im-
moral. Beauchamp and Childress not only justify the common mo-
rality normatively, they also justify it empirically by saying that the 
common morality can be demonstrated by empirical research. The 
purpose of such an empirical study would be to investigate wheth-
er cultural or individual differences emerge over our most general 
norms. Only persons committed to morality should be included in 
the study. Beauchamp and Childress suggest that it would be rea-
sonable to expect that all persons committed to morality accept the 
principle of nonmaleficence (it would be unbelievable that any 
person committed to morality would reject this principle). All per-
sons included in the study should thus be screened first to demon-
strate whether they accept the principle of nonmaleficence (Beau-
champ & Childress, 2013, pp. 305-308).
According to Beauchamp and Childress, the general principles of 
the common morality form the framework of our most abstract ob-
ligations.  These principles can be specified into more specific rules 
and still more specific norms. There is a transparent connection be-
tween principles and rules. For instance, the principle of respect for 
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autonomy can be specified into the rule of respecting the privacy of 
others, which can be specified into the norm of keeping personal 
information private and confidential (figure 5, next page). A rule 
can be justified by more than one principle; hence there is not a lin-
ear connection between rules and principles (personal communica-
tion with Beauchamp).
Beauchamp calls the universal system of principles, rules, and 
norms which constitutes morality wherever it is found ‘morality in 
the narrow sense’. From this view there is no difference in morality 
in China, Japan, Italy, and USA. Persons from these cultures com-
mitted to morality do defend the same general principles, rules, 
and norms. However, at the same time Beauchamp defends moral 
pluralism, since differences in morality are present in the way he 
calls ‘morality in the broad sense’. The diversity of moral positions 
is connected to the implementation, specification, and balancing of 
the universal system of principles, rules, and norms. Beauchamp 
General principles More specific rules Still more specific norms
Respect for autonomy Tell the truth
Respect the privacy of others
To tell about a health condition if discovered in 
research
Disclose material information in medical research
Keep personal information private and 
confidential
Nonmaleficence Do not cause pain or suffering of 
others 
Do not turn patients away from a hospital when 
seriously ill
Avoid as much pain and suffering as possible
Beneficence Prevent evil or harm from 
occurring
Help those who have disabilities
Balance benefits, costs, and risks
Use public health measures to protect from 
disease 
Protect subjects in research against excessive risk
Seek improvements in the quality of the 
environment
Justice Give equal consideration under 
the law
Provide equitable access to healthcare of 
appropriate quality 
Provide compensation for injury caused to 
research subjects
Figure 5. Principles, rules, and norms of the common morality (Personal communication with Beauchamp).
kvarter
a ademisk
academic quarter
Volume
12 216
A conceptual framework for the ethics of synthetic biology
Mette Ebbesen, Svend Andersen, Finn Skou Pedersen
writes: “Morality in the broad sense recognizes divergent and even 
conflicting moral positions created by different philosophical, reli-
gious, or cultural commitments […] here the many conflicting so-
cial codes across societies show significant dissimilarities of belief, 
but not so many dissimilarities that morality in the narrow sense is 
called into question” (Beauchamp, 1997, pp. 25, 27). 
The general principles of the common morality
According to Beauchamp, the four basic principles of the common 
morality are useful for dealing with complex cases of biomedicine. 
In figure 6, a short formulation of the four principles is presented. 
The principle of respect for autonomy
• “As a negative obligation: Autonomous actions should 
not be subjected to controlling constraints by others” 
(Beauchamp & Childress, 2013, p. 107).
• “As a positive obligation, this principle requires both 
respectful treatment in disclosing information and ac-
tions that foster autonomous decision making” (Beau-
champ & Childress, 2013, p. 107). Furthermore, this 
principle obligates to “disclose information, to probe 
for and ensure understanding and voluntariness, and 
to foster adequate decision making” (Beauchamp & 
Childress, 2009, p. 107).
The principle of beneficence
• One ought to prevent and remove evil or harm
• One ought to do and promote good (Beauchamp & 
Childress, 2013, p. 151).
The principle of nonmaleficence
“One ought not to inflict evil or harm”, where harm is 
understood as “thwarting, defeating, or setting back 
some party’s interests” (Beauchamp & Childress, 2013, 
pp. 152-153).
The principle of justice
Beauchamp & Childress argue that a single principle can-
not address all problems of distributive justice (Beau-
champ & Childress, 2009, p. 250). They defend a frame-
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work for allocation that incorporates both utilitarian and 
egalitarian standards. A fair healthcare system includes 
two strategies for healthcare allocation: 1) a utilitarian ap-
proach stressing maximal benefit to patients and socie-
ty, and 2) an egalitarian strategy emphasising the equal 
worth of persons and fair opportunity (Beauchamp & 
Childress, 2009, pp. 288, 293).
Figure 6. The four basic principles of the common morality. 
A brief formulation of the four ethical principles: the principles of re-
spect for autonomy, beneficence, nonmaleficence, and justice (Beauchamp 
& Childress, 2013; Ebbesen, 2009). 
These principles are prima facie binding in the sense that they are to 
be followed in every situation if they are not in conflict with other 
principles. This means that none of the principles is absolute. If 
two or more principles conflict they first need to be specified mak-
ing them adequate for the actual case at hand. According to Beau-
champ, “Specification is defined as a process of reducing the inde-
terminateness of general norms to give them increased action 
guiding capacity, while retaining the moral commitments in the 
original form” (Beauchamp, 2003, p. 269). Specification is a way of 
narrowing the scope of the norms, for instance by specifying where, 
when, who, why, how, and by whom the action has to be performed 
or eluded (Beauchamp, 2003, p. 269). The result of specification may 
be that the conflict of the principles is eradicated. If not, the princi-
ples or the specified norms have to be balanced. When principles 
are balanced, one principle is infringed by another. Balancing is 
about the weight and strength of the principles (Beauchamp & 
Childress, 2013, pp. 19-20). Beauchamp & Childress list six condi-
tions which constrain balancing and which must be met to justify 
the infringement of one prima facie principle by another (figure 7). 
When prima facie principles are specified and balanced, moral di-
versity may occur and this is what Beauchamp calls ‘morality in the 
broad sense’.
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The bioethical theory of Beauchamp and Childress is subject of seri-
ous debate, and several ethicists have discussed their ‘principlist’ 
approach and given suggestions for improvements (DeGrazia, 1992; 
Holm, 1995; Strong, 2000; King & Churchill, 2000; Rendtorff and 
Kemp, 2000; Rauprich, 2008). During the six editions of their work, 
Beauchamp and Childress have incorporated some of these sugges-
tions. However, it is not our task in this article to go into this debate.
Sociologist John Evans made a survey exploring how bioethics 
became institutionalized in the USA from 1980s into the 2000s. Ev-
ans observed that participants in the ethical debate specifically used 
the principle-based approach of Beauchamp and Childress and he 
criticised them for focusing specifically on autonomy (Yearley S, 
2009). Based on this focus on autonomy, Yearly is critical regarding 
the use of Beauchamp and Childress’ theory to analyse ethical is-
sues of synthetic biology. However, an approach focusing primarily 
on autonomy is not in line with Beauchamp and Childress’ theory, 
since in this theory the four principles are prima facie binding and 
hence, all four principles must be considered from the outset.
1. “Good reasons can be offered to act on the overriding 
norm rather than on the infringed norm”.
2. “The moral objective justifying the infringement has a 
realistic prospect of achievement”.
3. “No morally preferable alternative actions are availa-
ble”.
4. “The lowest level of infringement, commensurate with 
achieving the primary goal of the action, has been se-
lected”.
5. “Any negative effects of the infringement have been 
minimized”
6. “All affected parties have been treated impartially” 
(Beauchamp & Childress, 2013, p. 23).
Figure 7. Conditions constraining balancing. Conditions that must be 
met to justify infringement of one prima facie principle by another (Beauchamp 
& Childress, 2009; Ebbesen, 2013).
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Analyzing ethical issues of synthetic biology
To illustrate how Beauchamp and Childress’ theory can be used to 
analyze ethical issues of synthetic biology, we present a case where 
an oncolytic poxvirus has been engineered to replicate selectively 
in cancer cells and used as a vehicle for delivery and expression of 
transgenes in tumors (Breitbach et al., 2011; Cripe et al., 2015). This 
platform technology based on oncolytic viruses is an example of a 
synthetic product within biotechnology.
Breitbach et al. (2011) and Cripe et al. (2015) chose to use vaccinia, 
a large double-stranded DNA containing poxvirus, for intravenous 
delivery and expression of transgenes in tumors. These transgenes 
could for instance express therapeutic proteins or siRNAs (capable 
of silencing oncogenes). Vaccinia has biological properties which 
makes it appropriate for managing these tasks. Firstly, vaccinia 
is intravenous stable and spreads to distant tissues. Secondly, it 
spreads fast and is motile within tissues. Thirdly, it often deposits in 
tumors, and lastly, vaccinia replicates dependent on the EGFR/Ras 
(epidermal growth factor receptor) pathway signalling, which is 
generally activated in epithelial cancers (Breitbach et al., 2011). 
The oncolytic poxvirus (JX-594) was tested in a phase I clinical 
trial to investigate the dose-related fashion of tumor-specific in-
fection, replication, and expression of transgenes. Twenty-three pa-
tients with advanced treatment-refractory solid tumors were select-
ed for the trial and they underwent a single intravenous infusion of 
JX-594. JX-594 was mostly well tolerated; the most common side 
effects were flu-like symptoms lasting up to 24 h (Breitbach et al., 
2011). Breitbach et al. (2011) obtained biopsies 8-10 days after intra-
venous infusion and reported cancer-selective and dose-related JX-
594 delivery and replication in tumors. Furthermore, new tumor 
outgrowth in the time after infusion was not as frequent in patients 
treated with high doses as in to patients treated with low doses 
(Breitbach et al., 2011). Recently, a phase 2 dose-ranging study of 
Pexa-Vec in 30 patients with advanced liver cancer demonstrated 
increased survival in high dose Pexa-Vec  versus low dose (Cripe et 
al., 2015). Moreover, intratumoral dose escalation has been found to 
result in antitumor avtivity at high doses (Cripe et al., 2015).   
The first step in an ethical case analysis is to identify which ethi-
cal concerns, values, and principles are at stake in the actual case at 
hand. Therefore, in figure 8, we have presented ethical issues of 
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using cancer-targeted oncolytic poxvirus JX-594 for transgene ex-
pression in clinical trials. Generally, we believe that the following 
ethical concerns are important in all clinical trials: Informed consent 
of research subjects, expectations of therapeutic effects, risk analy-
sis of side effects of testing new methods, equitable access to clinical 
trials, and adequate compensation should be paid to research sub-
jects. Furthermore, this tumor specific oncolytic poxvirus is specifi-
cally designed to self-replicate in cancer cells expressing the EGFR/
Ras pathway signaling. Thereby, this system exemplifies the ethical 
concerns of ‘uncontrolled spread of self-replicating artificial sys-
tems’, mentioned earlier. And lastly, employees should be protect-
ed against virus infection. As illustrated in figure 8, ethical princi-
ples of beneficence, nonmaleficence, respect for autonomy and 
justice are important in the case at hand. The second step in the 
ethical analysis is to collect relevant clinical information (technical 
or scientific information) to perform a risk-benefit analysis regard-
ing the risk for ‘uncontrolled spread of self-replicating artificial sys-
tems’ and regarding possible side effects for research subjects. The 
third step is to consider whether some of the principles do conflict 
and whether they need to be specified or balanced.
In this article we have performed step one in the ethical analysis, 
hence we have identified which ethical considerations and basic 
ethical principles are at stake. We have not performed step two – to 
collect clinical information to make a risk-benefit analysis – and step 
three – to specify and balance ethical principles – since these steps 
require detailed information regarding the specific case at hand.
Ethical issues Ethical considerations Basic ethical principles
Protection of employees Health impact
Private sphere / informed 
consent
Beneficence
Nonmaleficence
Respect for autonomy
Uncontrolled spread of self-replicating 
artificial (non-natural) systems
Environmental impact
Health impact
Risk-benefit analysis
Beneficence
Nonmaleficence
Informed consent of research subjects in 
clinical trials
Informed consent Respect for autonomy
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Conclusion
In this article we have outlined a conceptual framework for the 
analysis of ethical issues of synthetic biology. Firstly, we showed 
that the ethical aspects of nanoscience are not new and unique since 
they are very similar to ethical issues of biotechnology, biology, and 
healthcare, and that basic ethical principles of nanoscience are part 
of the bioethical theory of Beauchamp and Childress (Ebbesen et al., 
2006). Secondly, we explained that the ethical issues of synthetic 
biology are similar to ethical issues of nanoscience, biotechnology, 
biology, and healthcare. We concluded that the principles of benefi-
cence, nonmaleficence, respect for autonomy, and justice are impor-
tant for synthetic biology and pointed out that these are part of 
Beauchamp and Childress’ theory. However, we do not claim that 
there could not be other principles to use. We argued that the theory 
of Beauchamp and Childress can therefore be used to analyze ethi-
cal issues of synthetic biology by going through the steps in an eth-
ical analysis using oncolytic poxvirus as a vehicle for delivery and 
expression of transgenes in tumors as a model case.
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